Ascendis Pharma A/S ASND
275.39 USD +8.32 (+3.12%)
At closeNov 13, 2026, 4:52 PM EST
275.39 0.00 0.00%
After hours · Nov 13, 4:52 PM ET
265.66 Day range 278.56
188.08 52-week range 282.15
- YTD
- +29.15%
- 1 year
- +33.39%
News
benzinga.com UBS Maintains Buy on Ascendis Pharma, Raises Price Target to $315 UBS analyst Joon Lee maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $269 to $315.
benzinga.com Wells Fargo Maintains Overweight on Ascendis Pharma, Raises Price Target to $330 Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $326 to $330.
benzinga.com RBC Capital Reiterates Outperform on Ascendis Pharma, Maintains $290 Price Target RBC Capital analyst Luca Issi reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $290 price target.
benzinga.com TD Cowen Maintains Buy on Ascendis Pharma, Raises Price Target to $352 TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $341 to $352.
benzinga.com Evercore ISI Group Maintains Outperform on Ascendis Pharma, Raises Price Target to $356 Evercore ISI Group analyst Josh Schimmer maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $326 to $356.
benzinga.com Cantor Fitzgerald Maintains Overweight on Ascendis Pharma, Raises Price Target to $315 Cantor Fitzgerald analyst Li Watsek maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $300 to $315.
benzinga.com HC Wainwright & Co. Maintains Buy on Ascendis Pharma, Lowers Price Target to $335 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $344 to $335.
marketbeat.com Ascendis Pharma A/S Q3 Earnings Call Highlights Ascendis Pharma A/S NASDAQ: ASND reported third-quarter product revenue of EUR 366 million, up 89% from a year earlier, as sales of hypoparathyroidism treatment YORVIPATH and recently launched…
seekingalpha.com Ascendis Pharma A/S (ASND) Q3 2026 Earnings Call Transcript Ascendis Pharma A/S (ASND) Q3 2026 Earnings Call Transcript
benzinga.com Ascendis Pharma Q3 2026 Earnings Call Transcript Ascendis Pharma (NASDAQ:ASND) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…- benzinga.com Ascendis Pharma Q3 Adj. EPS $1.97 Beats $1.13 Estimate, Sales $425.432M Beat $417.230M Estimate Ascendis Pharma (NASDAQ:ASND) reported quarterly earnings of $1.97 per share which beat the analyst consensus estimate of $1.13 by 74.34 percent. This is a 328.26 percent increase over earnings of…
globenewswire.com Ascendis Pharma Reports Third Quarter 2026 Financial Results Q3 2026 product revenue of €366 million (+89% Y/Y), comprising €291 million for YORVIPATH ® , €59 million for SKYTROFA ® , and €16 million for YUVIWEL ® Received positive CHMP and COMP opinions…
benzinga.com Cisco Systems, Applied Materials On Deck Thursday As AI Demand Faces Test Cisco Systems and Applied Materials headline Thursday’s reports, with investors looking for evidence that AI infrastructure demand can keep supporting semiconductor and networking growth. Brookfield,…
globenewswire.com Ascendis Pharma to Participate in the Jefferies London Healthcare Conference COPENHAGEN, Denmark, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Jefferies London…
benzinga.com Ascendis Pharma Says COMP Of EMA Adopts Positive Opinion Recommending Maintenance Of Orphan Medicinal Product Designation For Once-Weekly TransCon CNP As Treatment For Achondroplasia In Children Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending…
globenewswire.com Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union – Final European Commission decision expected during Q4 2026 COPENHAGEN, Denmark, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Orphan…
globenewswire.com Ascendis to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026 COPENHAGEN, Denmark, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report third quarter 2026 financial results and provide a business update on…- benzinga.com Ascendis Pharma Reports Sustained Kidney Function Improvements Over 5-Years With TransCon PTH In Adults With Hypoparathyroidism Ascendis Pharma A/S (NASDAQ:ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with…
globenewswire.com TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years COPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney…- benzinga.com Ascendis Pharma Receives Positive Opinion From Committee For Medicinal Products For Human Use Of European Medicines Agency For Marketing Authorization Of TransCon CNP In EU To Treat Achondroplasia Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending…
globenewswire.com Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children COPENHAGEN, Denmark, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines…
benzinga.com Here’s How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 13.7% on an annualized basis producing an average annual return of 27.5%. Currently, Ascendis Pharma has a market…
zacks.com FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.
globenewswire.com Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026 COPENHAGEN, Denmark, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest advances in its hypoparathyroidism and achondroplasia programs will be…
benzinga.com Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 14.04% on an annualized basis producing an average annual return of 27.55%. Currently, Ascendis Pharma has a market…
defenseworld.net Ascendis Pharma A/S’s (ASND) “Overweight” Rating Reaffirmed at Cantor Fitzgerald Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report)'s stock had its "overweight" rating restated by equities research analysts at Cantor Fitzgerald in a report released on Friday, Benzinga reports.…
seekingalpha.com Ascendis Pharma: Back To Full Independence Ascendis Pharma faces negative sentiment after Novo returned TransCon rights, compounding prior partner exits and pipeline disappointments. Despite pipeline contraction, ASND's approved…
seekingalpha.com Ascendis Pharma A/S (ASND) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Ascendis Pharma A/S (ASND) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
benzinga.com Why Is Ascendis Pharma Stock Trading Lower on Tuesday? Ascendis Pharma A/S (NASDAQ:ASND) shares are trading lower on Tuesday as investors digest news that the company will regain rights to certain TransCon technology-based programs and a share buyback.
benzinga.com Why Is Ascendis Pharma Stock Trading Lower on Tuesday? Ascendis Pharma shares dip as it reclaims TransCon technology rights from Novo Nordisk and initiates a $400 million share repurchase program.
benzinga.com 10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.
benzinga.com This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Analysts downgraded Banco Santander Brasil, Ribbon Communications, Cellectis, Scholar Rock, with mixed price-target changes.- benzinga.com Raymond James Downgrades Ascendis Pharma to Outperform, Maintains Price Target to $287 Raymond James analyst Martin Auster downgrades Ascendis Pharma (NASDAQ:ASND) from Strong Buy to Outperform and maintains the price target from $287 to $287.
- benzinga.com Ascendis Pharma Authorizes Up To $400M Share Repurchase Program Ascendis Pharma A/S (NASDAQ:ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company’s ordinary shares (the Share Repurchase…
benzinga.com Ascendis Pharma Regains Exclusive Rights To TransCon Tech Products After Ending Novo Nordisk Collaboration; Ascendis To Initiate Multiple Programs In Metabolic And Cardiovascular Diseases, Including Obesity - All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis- Ascendis to initiate multiple…
globenewswire.com Ascendis Announces Planned $400 Million Share Repurchase Program COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of…
globenewswire.com Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases - All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis- Ascendis to initiate multiple…- benzinga.com $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 16.08% on an annualized basis producing an average annual return of 29.64%. Currently, Ascendis Pharma has a market…
defenseworld.net Head-To-Head Analysis: Ascendis Pharma A/S (NASDAQ:ASND) versus MeiraGTx (NASDAQ:MGTX) Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report) and MeiraGTx (NASDAQ: MGTX - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two…
benzinga.com Ascendis Pharma Says Growth Drug Shows Benefits in Infants Ascendis Pharma released positive 52-week data for TransCon CNP in infants with achondroplasia from its Phase 2 reACHin trial.- benzinga.com Ascendis Announces Week 52 Data From Open-Label Sentinel Cohort Portion Of reACHin Trial Showing Treatment With Once-Weekly TransCon CNP Provided Stabilization Or Improvement In Foramen Magnum Stenosis And Linear Growth Benefits In Infants With Achondroplasia – Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment – Treatment with TransCon CNP increased linear growth in the sentinel cohort,…
globenewswire.com First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026 – Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment
globenewswire.com Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference COPENHAGEN, Denmark, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Morgan Stanley 24th…- benzinga.com Reported Earlier, Ascendis Pharma To Present New Infant Achondroplasia Trial Data At ESPE 2026 Ascendis Pharma A/S (NASDAQ:ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual congress of the European Society for…
globenewswire.com Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026 COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026,…- benzinga.com Oppenheimer Maintains Outperform on Ascendis Pharma, Raises Price Target to $312 Oppenheimer analyst Leland Gershell maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $304 to $312.
benzinga.com Morgan Stanley Maintains Overweight on Ascendis Pharma, Lowers Price Target to $273 Morgan Stanley analyst Maxwell Skor maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $275 to $273.- benzinga.com Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $327 Price Target Wedbush analyst Yun Zhong reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $327 price target.
benzinga.com Oil Jumps Near $90 On Iran Risk, California Utilities Crater: Stock Market Today Brent climbed after new U.S.-Iran strikes, pushing the 10-year yield to a 19-month high; Edison and PG&E collapsed on a wildfire bill.- benzinga.com B of A Securities Maintains Buy on Ascendis Pharma, Lowers Price Target to $304 B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $306 to $304.